These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 30300292)

  • 1. Hallucinogen Persisting Perception Disorder After Ibogaine Treatment for Opioid Dependence.
    Knuijver T; Belgers M; Markus W; Verkes RJ; van Oosteren T; Schellekens A
    J Clin Psychopharmacol; 2018 Dec; 38(6):646-648. PubMed ID: 30300292
    [No Abstract]   [Full Text] [Related]  

  • 2. A Mixed-Method Analysis of Persisting Effects Associated with Positive Outcomes Following Ibogaine Detoxification.
    Davis AK; Renn E; Windham-Herman AM; Polanco M; Barsuglia JP
    J Psychoactive Drugs; 2018; 50(4):287-297. PubMed ID: 30020025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the toxicity and therapeutic potential of ibogaine in the treatment of chronic opioid abuse.
    Luz M; Mash DC
    Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1019-1022. PubMed ID: 34139922
    [No Abstract]   [Full Text] [Related]  

  • 4. Ibogaine and Subjective Experience: Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder.
    Brown TK; Noller GE; Denenberg JO
    J Psychoactive Drugs; 2019; 51(2):155-165. PubMed ID: 30967101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonidine treatment for hallucinogen persisting perception disorder.
    Lerner AG; Finkel B; Oyffe I; Merenzon I; Sigal M
    Am J Psychiatry; 1998 Oct; 155(10):1460. PubMed ID: 9766785
    [No Abstract]   [Full Text] [Related]  

  • 6. Ibogaine for treating drug dependence. What is a safe dose?
    Schep LJ; Slaughter RJ; Galea S; Newcombe D
    Drug Alcohol Depend; 2016 Sep; 166():1-5. PubMed ID: 27426011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remission of Severe Opioid Use Disorder with Ibogaine: A Case Report.
    Cloutier-Gill L; Wood E; Millar T; Ferris C; Eugenia Socias M
    J Psychoactive Drugs; 2016; 48(3):214-7. PubMed ID: 27192438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine.
    Malcolm BJ; Polanco M; Barsuglia JP
    J Psychoactive Drugs; 2018; 50(3):256-265. PubMed ID: 29608409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to Luz & Mash on cardiac toxicity of ibogaine.
    Schellekens A; Kramers K; Knuijver T; Belgers M; Donders R; Verkes RJ
    Addiction; 2022 Mar; 117(3):837-838. PubMed ID: 34859515
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes.
    Brown TK; Alper K
    Am J Drug Alcohol Abuse; 2018; 44(1):24-36. PubMed ID: 28541119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hallucinogen Persisting Perception Disorder and Risk of Suicide.
    Brodrick J; Mitchell BG
    J Pharm Pract; 2016 Aug; 29(4):431-4. PubMed ID: 25631475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients.
    Knuijver T; Ter Heine R; Schellekens AFA; Heydari P; Lucas L; Westra S; Belgers M; van Oosteren T; Verkes RJ; Kramers C
    J Psychopharmacol; 2024 May; 38(5):481-488. PubMed ID: 38519421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hallucinogen persisting perception disorder after psilocybin consumption: a case study.
    Espiard ML; Lecardeur L; Abadie P; Halbecq I; Dollfus S
    Eur Psychiatry; 2005 Aug; 20(5-6):458-60. PubMed ID: 15963699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychedelic Therapy: A Primer for Primary Care Clinicians-Ibogaine.
    Cherian K; Shinozuka K; Tabaac BJ; Arenas A; Beutler BD; Evans VD; Fasano C; Muir OS
    Am J Ther; 2024 Mar-Apr 01; 31(2):e133-e140. PubMed ID: 38518270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic Cannabis Substances (SPS) Use and Hallucinogen Persisting Perception Disorder (HPPD): Two Case Reports.
    G Lerner A; Goodman C; Bor O; Lev-Ran S
    Isr J Psychiatry Relat Sci; 2014; 51(4):277-80. PubMed ID: 25841224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention, and treatment.
    Doyle MA; Ling S; Lui LMW; Fragnelli P; Teopiz KM; Ho R; Di Vincenzo JD; Rosenblat JD; Gillissie ES; Nogo D; Ceban F; Jawad MY; McIntyre RS
    Expert Opin Drug Saf; 2022 Jun; 21(6):733-743. PubMed ID: 35426769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of death due to ibogaine use for heroin addiction: case report.
    Jalal S; Daher E; Hilu R
    Am J Addict; 2013; 22(3):302. PubMed ID: 23617876
    [No Abstract]   [Full Text] [Related]  

  • 18. Hallucinogens: an update.
    Halpern JH
    Curr Psychiatry Rep; 2003 Oct; 5(5):347-54. PubMed ID: 13678554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-QT syndrome induced by the antiaddiction drug ibogaine.
    Hoelen DW; Spiering W; Valk GD
    N Engl J Med; 2009 Jan; 360(3):308-9. PubMed ID: 19144953
    [No Abstract]   [Full Text] [Related]  

  • 20. [Synesthesias in the context of hallucinogen-induced persistent perception disorder following the use of lsd].
    Neven A; Blom JD
    Tijdschr Psychiatr; 2014; 56(11):748-52. PubMed ID: 25401683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.